Found 3 articles for: "Secukinumab"
Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis
February 2024 | Volume 23 | Issue 2 | Original Article | 74 | Copyright © February 2024
Early response to treatment with biologics, defined as Psoriasis Area and Severity Index (PASI) of 2 or less six months after initiation of therapy, seems to be associated with more stable psoria...
Read MoreAtopic Dermatitis as a Paradoxical Reaction to Secukinumab in a Patient With Plaque Psoriasis
February 2024 | Volume 23 | Issue 2 | Case Reports | 97 | Copyright © February 2024
Paradoxical reactions to biologic agents used in the treatment of psoriasis are rare but have been reported with tumor necrosis factor (TNF) blockers and, more recently, with interleukin (IL)-17A...
Read MoreNovel Regimen of IL-17A Inhibitor Secukinumab for the Remission of Severe Hidradenitis Suppurativa: Case Report
December 2022 | Volume 21 | Issue 12 | Case Reports | 1358 | Copyright © December 2022
Hidradenitis suppurativa (HS) is a morbid, recurrent skin condition that presents a major challenge to clinical therapy. Investigation into the pathogenesis of HS has implicated local and systemic pro...
Read More
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.